Published in

Nature Research, npj Precision Oncology, 1(4), 2020

DOI: 10.1038/s41698-020-00134-3

Links

Tools

Export citation

Search in Google Scholar

On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer

Journal article published in 2020 by Tina Moser ORCID, Julie Waldispuehl-Geigl, Jelena Belic, Sabrina Weber, Qing Zhou, Samantha O. Hasenleithner ORCID, Ricarda Graf, Jasmin Alia Terzic, Florian Posch, Heinz Sill ORCID, Sigurd Lax ORCID, Karl Kashofer, Gerald Hoefler, Helmut Schoellnast, Ellen Heitzer ORCID and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

AbstractWe addressed a significant unknown feature of circulating tumor DNA (ctDNA), i.e., how ctDNA levels change during chemotherapy, by serially monitoring ctDNA in patients with colorectal cancer during the 48-h application of FOLFOX. Surprisingly, we did not observe a spike in ctDNA as a sign of a responsive tumor, but instead ctDNA levels initially decreased and remained low in patients with stable disease or partial response. Our observations reveal further insights into cell destruction during chemotherapy with important implications for the management of patients.